Sign In   |   Register


Breaking News:

Breaking News

8-22-19 Trickle Research Initiates Research
 Cavitation Technologies, Inc. OTCQB CVAT 
12-24 Month Price Target $0.10
Click Here>>

 9-6-19 Greenridge Global Equity Research Issues Updates
Guangdong Land Holdings, Ltd.
Click Here>>

8-20-19 Canbiola, Inc. (OTCQB:CANB)
Canbiola Reports Second Quarter 2019 Results

Click Here For Press Release

8-7-19 Trickle Research issues update and allocation increase to 6
Camino Minerals Corp  OTC: CAMZF TSXV: COR.V
12-24 Month Price Target $0.90

Click Here For Update Report

Trickle Research issues update and allocation increase to 7
AzurRx Biopharma, Inc.  7-11-19
12-24 Month Price Target $10.25

Click Here for Update Report

6-6-19 Greenridge Global Equity Research
Issues Update
Guangdong Land Holdings, Ltd.
Maintaining rating and Buy target HK$ 4.75
Click Here>>

6-4-19 Trickle Research Issues Allocation Update Report
Summit Wireless Technologies, Inc. Nasdaq (WISA) 
12-24 Month Price Target $9.25

Allocation 5
Click Here>>

4-9-19 Trickle Research Initiates Research
H Source Holdings, Ltd., TSXV (HSI.V) OTCQB (HSCHF) 
12-24 Month Price Target $0.19
Click Here>>

5-20-18 Trickle Research Issues Update Report
Alvopetro Energy, Ltd., TSXV (ALV.V) OTC (ALVOF) 
12-24 Month Price Target $1.10
Clcik Here>>

4-29-19 Greenridge Global Equity Research Issues Updates
Guangdong Land Holdings, Ltd.
Click Here>>

Chardan Research Earnings Update 4-19-19
  Social Reality Inc. (SRAX)
Target Price $10.00

Click Here for Report

4-17-19 Canbiola, Inc. (CANB)
Canbiola Announces Fourth Quarter and Full Year 2018 Results

Click Here for Complete Release

Trickle Research Earnings Update 4-16-19
  Social Reality Inc. (SRAX)
12-24 Month Target Price $15.00

Click Here for Report

Trickle Research Fiscal 2018
& Merger Announcement Update Update 4-10-19
12-24 Month Target Price $8.75

Click Here for Report

3-28-2019 Endurance Exploration Group, Inc. (EXPL)

Blue Water Ventures International, Inc. and Project Partner Endurance Exploration Group, Inc. Announce Preparations for 2019 Operations

Read Complete Press Release>>

3-11-19 Canbiola, Inc. (CANB) Canbiola is Registered and Active in the GSA’s System for Award Management (SAM) and Department of Defense (DOD)
Read Complete Press Release>>

Trickle Research issues update of
AzurRx Biopharma, Inc.  2-26-19
12-24 Month Price Target $10.25

Click Here for Update Report

Trickle Research Earnings Update 2-9-19
  Social Reality Inc. (SRAX)
12-24 Month Target Price $9.25

Click Here for Report




  Black Swan Research
Research Coverage 4-19
SMM is now hosting Equity Research and updates from top tier research providers:           
 Trickle Research
Click here to Subscribe to Trickle Research 
 Falcon Strategic Research
 Consilium Global Research
 Click Here to Subscribe to Black Swan Research

Black Swan Newsletter



August 2019

Click here to view

Our goal with the Black Swan Connection is to provide our subscribers, investors and financial professional compatriots outstanding investment insight that is a step above and outside of what will normally be found in mainstream financial press. To that end we have brought together seasoned, successful, and some of the brightest professionals in their respective fields to provide the articles and advice that is based on decades of practice in the field.

Breaking News

Tesla is a story we’ve been covering for a while- No good news here…..

Slumping Tesla Stock Headed Into Test of 2019 Low

Controversial automaker Tesla, Inc. (TSLA) is slumping badly in this tough summer market, dropping like a rock after a six-week oversold rally reversed in July at major resistance between $250 and $270. Adding to growing shareholder anxiety, the stock just broke intermediate support near $230, exposing a second trip into the psychological $200 level and a critical test at June's three-year low at $176.99. First, Wall Street is concerned Tesla doesn't have a viable path to profitability after it reported a much greater-than-expected loss in July's quarterly report.

Read Full Commentary


Feature Article

For Microcaps…Its Rough Out There

By: Dave Lavigne

August 2019

I have been providing independent microcap stock research under my own labels since 2002.  Prior to that, I provided the same on the sell side for small regional broker dealers, and that included research as a part of those entities’ corporate finance due diligence. I have been at this a while.

Over those periods that I was preparing research for “public consumption” I kept a track record of  sorts comparing my research universe to that of the performances of three major U.S. equity indices; the Dow Jones Industrial Average, the NASDAQ and the S&P 500. Over much of that period, (and over reasonable periods of time) my research universes typically outperformed those indices, and often by meaningful margins.  As a matter of full disclosure, there are a number of nuances that impact the relevance of those comparisons (transaction costs, spreads, liquidity etc.), so I fully submit, while the stock picks as whole have performed well, I am certainly no guru, and comparing the picks to those indices has some holes. 

Read Complete Article

8-2-19 Canbiola, Inc. (OTCQB:CANB)

Canbiola Launches Dedicated Canbiola-Branded CBD Dispensing Machine

Initial 25 Units Will Target Medical Offices

HICKSVILLE, NY, Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer, and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, isolate, gel caps, and concentrate announced today the launch of its own Canbiola-branded CBD product dispensing machine. An initial order for the first 25 units has been placed with the installations expected to occur in August and September.

Read Complete Press Release


7-16-19 Antibe Therapeutics, Inc. TSXV:ATE, OTCQB:ATBPF)

Antibe Therapeutics Reports 2019 Year-End Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF) filed its financial and operating results on Tuesday, July 16 for the fourth quarter and the year ended March 31, 2019. The Company's audited 2019 consolidated financial statements, MD&A and AIF are available on SEDAR.

About Antibe Therapeutics Inc.
Antibe develops safer, non-addictive medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation.

Read Complete Press Release

InvestorsHub News Wire:



Weekly Update: Sept 11th, 2019

Breaking News

Reuters 9-12-19

Stocks Climb, bond yields off lows, on trade progress hopes

New York, Sept 12 (Reuters)- A gauge of stock markets touched its highest since late Thursday after fresh hints of progress in US-China trade dispute, sending bond yields off lows hit earlier in wake of the European Central Banks new stimulus measures.

Read Complete Report


9-4-19 Greenridge Global Equity Research Issues Updates
Guangdong Land Holdings, Ltd. HKSE 0124

Sales Continues At All Portfolio Properties

Unit Sales Continue Across Property Portfolio.  GDL reported first half results with Revenue of HK$464.1 million, which was generated from the delivery of 4,440m2 from Laurel House, 102m2 from Baohuaxuan, and 2,186m2 of residential space and 207m2 of car parking spaces at Ruyingju.  Pre-sales of GDH City during the period was 4,991m2.  Cost of Sales was HK$344.5 million, for a Gross Profit of HK$119.6 million, or 25.8%.  SG&A was HK$80.9 million, up significantly reflecting the greater number of projects GDL owns and increased marketing activity at GDH City.  Included in the marketing activities was a well-attended project kick-off event on June 14 for prospective buyers, renters and other partners.  Net Finance Expense was HK$35.8 million and Income Tax Expense was HK$47.2 million, which was partially offset by HK$17.0 million in Other Income, most of which was from Foreign Currency Gains.  Net Loss for the period was HK$27.4 million, or 1.98 cents per share, far below our estimate as we had assumed much faster sales of the Laurel House project.

N Land Contract Amendment.  On July 4, GDL amended its foundation pit support, earth and stone works, and piling works agreement with the contractor for its Northern Land site of GDH City, which will see GDL pay an additional HK$44.9 million.  The amendment was made primarily to account for the change in policy in Shenzhen requiring off-road vehicles to be new energy vehicles, which has markedly increased to cost to transport materials.  The change will ultimately result in a six month delay from the original timeline with this contractor, however management still believes the entirety of the N Land project will be completed as scheduled.

Related Party Sale - Laurel House Units.  On September 2, GDL announced it was selling a total of seven units from the Laurel House project to a subsidiary of its ultimate parent company, Guangdong Holdings.  A total of 692.65m2 was sold for cash at an average price of RMB 70,367 per m2, which falls in line with market prices.  GDL expects to report a net profit of RMB 2,642,000 from the sale of these units.  On July 18, GDL renewed its property management agreement with Yuehai Property Management for Laurel House, which now runs through 2020

Model Update.  Changes to our model include lengthening the time to contract and deliver units at Laurel House, increasing development expenses for GDH City as noted above, and making adjustments for the depreciation of the RMB relative to the HKD.

Maintaining Rating & Reducing Target.  The model changes noted above resulted in a reduction in our DCF valuation of the Company, from HK$4.75 to HK$4.25.  However, with GDH City making progress in terms of construction timeline and partner/tenant negotiations, we continue to believe GDL’s stock is undervalued at current prices.  As such we are reiterating our Buy rating on Guangdong Land.  Our target price is based on our DCF model that covers GDL’s entire project portfolio, discounted at 6.5%.

Click Here>>


7-27-19 Antibe Therapeutics, Inc. TSXV:ATE, OTCQB:ATBPF)

Antibe Therapeutics Provides Update on Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today provides an update on the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The clinical study commenced in March 2019 and is designed to validate the efficacy of ATB-346 in reducing pain and establish the dose for Phase 3 development. A total of 360 patients with osteoarthritis of the knee are being randomized to either placebo or one of three doses of ATB-346 administered once daily: 150 mg, 200 mg or 250 mg.

Read Complete Press Release

Community Search
Sign In